Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Glofitamab, Poseltinib and Lenalidomide in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma

NCT05335018 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT05335018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05335018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Glofitamab, Poseltinib and Lenalidomide in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma
Lead sponsor
Seoul National University Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 30, 2022
Completion date
November 30, 2026
Enrollment
76 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory diffuse large b cell lymphoma